Published on April 1, 2026
The attorneys general of Texas and Arizona have filed a lawsuit against Cord Blood Registry (CBR), alleging that the company engaged in false advertising practices that misled new parents about the benefits of storing umbilical cord blood. The legal action, announced on Wednesday, accuses CBR of profiting from deceptive claims that overstated the medical benefits of their services.
According to the complaints lodged states, CBR advertised that storing cord blood could potentially cure various diseases and conditions, including cancers and genetic disorders. However, the attorneys general assert that these assertions lacked scientific backing and misled parents into believing that cord blood storage was a necessary and lifesaving decision.
The lawsuit comes at a time when more parents are considering banking their babies’ cord blood, which is rich in stem cells. While proponents highlight the potential uses of these stem cells in treating specific medical conditions, critics argue that the chances of a child needing their stored cord blood in their lifetime are extremely low. Nevertheless, CBR marketed their services aggressively, emphasizing the promise of future medical advancements, according to the allegations from Texas Attorney General Ken Paxton and Arizona Attorney General Kris Mayes.
In response to the lawsuit, a spokesperson for CBR denied the claims, stating that the company’s marketing is based on scientific data and medical research. They assert that the benefits of cord blood storage are real and that parents deserve to be informed of their options. CBR’s management emphasized their commitment to transparency and patient education in the rapidly evolving field of regenerative medicine.
Both Texas and Arizona are seeking restitution for consumers, as well as penalizing action against CBR for its allegedly misleading marketing practices. This case highlights the ongoing debate surrounding the commercialization of stem cell therapies and the ethical considerations tied to advertising medical advancements to families.
As legal proceedings unfold, the outcomes may prompt regulatory scrutiny in the stem cell banking industry and potentially reshape how companies market their services to expectant parents.
Related News
- Why forcing employees to use AI is producing the opposite of what companies want
- Once a luxury for moms, doula care is going mainstream
- <a href="http://news.xinhuanet.com/english/photo/2017-03/29/c_136165801.htm" target="_blank">In pics: Sunset scenery of Dead Sea</a>
- How the World Bank became a permanent actor in India’s coastal policy
- Mohamed Salah announces Liverpool departure, ending nine-year stint that made him club legend
- OnlyFans billionaire owner dies